The Clarivate for Life Sciences & Healthcare 'Companies to Watch: Rediscovering Women's Health' report spotlights seven trailblazing companies transforming the women's health landscape – and our portfolio company Freya Biosciences is among them.

Freya is pioneering a groundbreaking approach to reproductive and maternal health by harnessing the power of the vaginal microbiome. Using its proprietary DYSCOVER™ platform – a sophisticated multi-omics data science system – Freya is developing microbial immunotherapies to address chronic inflammation underlying conditions from bacterial vaginosis to infertility and preterm birth prevention.

The Clarivate report, which examines companies driving innovation across contraception, menopause management, endometriosis, fertility, and mental health, underscores a critical reality: women's health represents a $1 trillion opportunity, yet remains chronically underfunded relative to its burden of disease. Companies like Freya are proving that cutting-edge science, bold entrepreneurship, and a commitment to health equity can reshape possibilities for millions of women worldwide.

Discover how Freya and six other innovators are redefining women's health and why this moment matters for patients, investors, and the industry.

Read the full report here